DarioHealth Launches Its Dario App in the Google Play Store Expanding Its U.S. Market Reach
After receiving clearance for certain leading Android devices, DarioHealth expects to accelerate growth for its U.S. user base
Sep 7, 2017
CAESAREA, Israel, Sept. 7, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the launch of its Dario app for certain leading Android smart mobile devices (SMD) in the U.S. The company's Dario Blood Glucose Monitoring System (BGMS) is now available and ready to ship its to Android users in the U.S.
This launch opens a significant U.S. market opportunity for DarioHealth, as its flagship Dario app is now available in Google Play's U.S. app store for specific SMDs to be used with the Dario BGMS.
Erez Raphael, Chairman and CEO of DarioHealth, commented, "We are very excited to have reached this release date for the Dario app on certain Android devices. With this launch, the Dario app now accessible to many more SMD users in the U.S. This continues DarioHealth's U.S. market progress, and opens the door for potential wide-scale expansion in this pivotal market. The Dario BGMS is an affordable device that simplifies diabetes management for people with diabetes via their smartphone. With the Android availability, we believe we are poised to continue our sequential quarterly growth and hope to make 2017 a record-breaking year."
Dror Bacher, COO of DarioHealth, commented, "Our products have undergone rigorous testing to ensure they meet the highest standards. I believe Android users in the U.S. will be very pleased with our product offering, which is fairly priced and on par with many insurance co-pay plans."
The compact all-in-one system helps people with diabetes monitor their blood sugar levels and proactively manages their diabetes using their smartphone. Dario connects via a headphone jack to turn a mobile device into a glucose monitor, and incorporates a lancing device and test strips together with the meter in an all-in-one easy to carry device to take blood glucose measurements on the spot. Unlike conventional glucose monitors, there is no carrying case or batteries to replace. Dario provides real-time and historical blood glucose data to allow health care providers to spot patterns, recommend treatments and support behavior changes. Dario's web interface also makes it easy for users to share health information with healthcare providers and loved ones.
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company states that the Dario application for certain Android devices opens a significant market opportunity and the potential for wide-scale expansion in the U.S., and that with the Android availability, it believes it is poised to continue its sequential quarterly growth and hopes to make 2017 a record-breaking year, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate and Media Contact
DarioHealth Investor Relations Contact
SOURCE DarioHealth Corp.